ABSTRACT 1 SOX9, a high mobility group (HMG) box transcription factor, plays critical roles during 2 embryogenesis and its activity is required for development, differentiation and lineage 3 commitment in various tissues including the intestinal epithelium. Here, we present 4 functional and clinical data of a broadly important role for SOX9 in tumorigenesis. 5 SOX9 was overexpressed in a wide range of human cancers, where its expression 6 correlated with malignant character and progression. Gain of SOX9 copy number is 7 detected in some primary colorectal cancers. SOX9 exhibited several pro-oncogenic 8 
domains (1) . However, their action on target genes is context dependent, relying on 27 other transcription factors with which they may directly interact for specificity (1) . SOX 28 proteins coordinate disparate functions, such as maintaining stem cell properties, 29 lineage restriction and terminal differentiation, through precise temporal and spatial 30 expression patterns that differ between particular cell types and tissues (2) . In particular, 31 SOX9 plays a pivotal role in a number of developmental processes and its levels need to 32 be strictly controlled for normal embryogenesis. In humans, SOX9 heterozygous 33 mutations result in Campomelic Dysplasia (CD), a syndrome characterized by severe 34 skeletal malformations, defects in the CNS and several other organs, frequent XY 35 female sex reversal, and perinatal lethality (3) . In mice, Sox9 homozygous null mutant 36 embryos die around embryonic day 12 (E12) due to heart defects, while heterozygotes 37 die around birth with phenotypes similar to human CD patients, although without sex 38 reversal (4). In addition, duplications of the Sox9 gene, or its deliberate misexpression 39 have been linked with XX male sex reversal and fibrosis-related disorders (5, 6) , and 40 demonstrate that dysregulation of the gene can cause disease. Further analyses have 41 shown that SOX9 is crucial for Sertoli cell differentiation, chondrogenesis, neural crest 42 development and differentiation of some of its derivatives, as well as, for the 43 development of specific cell types and lineages within the CNS, pancreas, prostate 44 intestine, skin, pituitary, heart, kidney and sensory systems (7) . 45 Colorectal cancer is the third leading cause of cancer-related deaths world-wide 46 and its incidence is steadily increasing (8) . Colorectal carcinomas derive from the 47 intestinal epithelium, which is constantly self-renewing and requires a high rate of cell 48 division to maintain epithelial homeostasis (9) was sequenced using an on-site sequencing service. The transgene fragment was 90 released with SalI/NotI digestion, and was purified for pronuclear injection into 91 fertilized eggs of B10/CBAF1 mice. Sox9
Flox/flox and Z/Sox9 mice were maintained on a 92 mixed C57BL6/129 genetic background. Isolation, culture, and assays with mouse 93 embryo fibroblasts (MEFs) were carried out as previously described (25) 
For SOX9 or Bmi1 knockdown by shRNA: Cells were transfected using 96
Lipofectamine (invitrogen), according to instructions of the reagent supplier. Cells were 97 cultivated in the presence of puromycin for 3 weeks. Cells were transfected using two 98 different Sox9 shRNAs (Origene, sh1 or sh75 and sh2 or sh73) and shRNA especific for 99 BMI1. A non-specific shRNA (pRS) was used as a control. 100
101

RNA and protein analysis 102
Total RNA was extracted with Trizol (Life Technologies). Reverse transcription was 103 performed using random priming and Superscript Reverse Transcriptase (Life 4°C. Subsequent to blocking for 1h with PBS and 1% FCS, cells were incubated with 122 P-H3 (Chemicom) antibody for 2h. Secondary antibodies were from Jackson. Nuclear 123 DNA was stained with a 4% PBS buffered paraformaldehyde solution containing 10 124 µg/ml 4'6-diamidino-2-phenylindole (DAPI, Sigma). 125
Chromatin immunoprecipitation (ChIP) assays -ChIP assays were performed 126 according to standard procedures (see supplementary information). DNA fragments 127
were immunoprecipitated with antibodies against Sox9 (Chemicon), H3K4me3, 128
H3K9me3 and H3K27me3 (Millipore). The immunoprecipitated DNA was extracted 129 and subjected to PCR amplification with primers directed against the proximal promoter 130 of Bmi1 or Sox9 respectively. 131
Histopathology and immunohistochemistry 132
Murine tissues were dissected, fixed in 10%-buffered formalin (Sigma) and embedded 133 in paraffin. Three-micrometer-thick sections were stained with hematoxylin and eosin 134 (H&E). Antibodies used for immunohistochemistry analysis included rabbit polyclonal 135 anti-Sox9 (1:200 dilution, Millipore); A Dako automated system was used for the 136 immunostaining after antigen retrieval in a PTLink (Dako). 137
Tumor samples and array CGH datasets 138
Human Tissue Microarrays (TMAs) were obtained from the CNIO Tumor Bank Unit. 139
Human colorectal carcinoma samples and data from patients were provided by the 140
Basque Biobank for Research-OEHUN (http://www.biobancovasco.org) and two 141 independent transcriptome profiling datasets previously described (26, 27) . The raw 142 data are accessible through the NCBI's Gene Expression Omnibus public repository for 143 microarray data (accession numbers GSE25071 and GSE24550). Samples were 144 processed following standard operation procedures with appropriate ethical approval. 145
The array-comparative genomic hybridization (CGH) data were recently generated (28) . 146
Here, the NimbleGen Human Whole-Genome Array CGH Analysis v1 (Roche 147 Diagnostics, Mannheim, Germany), was applied, which provides measurements from 148 385 000 unique genomic loci. 149
In vivo carcinogenesis assays 150 respectively compared to non-tumor colonic mucosa (Fig 1B) . Furthermore, when we 202 analyzed SOX9 levels in relation to tumor stage, we found that higher levels of SOX9 203 mRNA were associated with advanced tumor stage (Fig. 1C) . High levels of SOX9 were 204 found both in carcinomas of the colon and rectum (Fig. Suppl 3) . From high resolution 205 array-CGH data we found that some carcinoma samples (7%) had low copy number 206 gain at the distal part of chromosome 17, including the SOX9 gene (Fig. 1D, Fig. Suppl  207   4 ). The gain is observed at low level and in few samples implying that copy number 208 change is a plausible but not exclusive mechanism, for the increase of SOX9 expression 209 in colorectal carcinoma. Consistent with the tissue data, SOX9 was generally highly 210 expressed in human colorectal cancer cell lines, with levels ranging from 1.5 to 30 times 211 higher than in normal colonic mucosa (Fig. 1E,F, Fig. Suppl. 3 ). In particular, SOX9 212 expression was remarkably higher in SW620 than in SW480 (Fig. 1F,G Fig. 2A,B analysis. The numbers of Z/Sox9tg cells in S-phase were higher and those in G1 lower 253 when compared to wt cells (Fig. 2G) . Conversely, the number of Sox9 Δ/Δ MEFs in S-254 phase was reduced compared to controls (Fig. 2G) . Together, our results support the 255 idea that Sox9 regulates proliferation in primary cells controlling the progression of the 256 cell cycle from G1 to S phase. 257
Having established that SOX9 promotes proliferation in MEFs, we moved to a 258 more relevant cellular setting by analyzing human colorectal cancer cells. We focused 259 on HCT116 and SW620 because they express very high levels of SOX9 (Fig. 1 G) . Sub-260 lines were derived after stable introduction of two independent SOX9 shRNAs. We 261 obtained similar results but we present the protein and mRNA data obtained with the 262 most efficient shRNA (sh1) (Fig. 2H,I ). Downregulation of SOX9 levels resulted in a 263 reduction in proliferation as measured by cell growth curves and phospho-histone H3 264 (P-H3) immunostaining ( 
6). It is well established that Arf 286
stabilizes p53, another major regulator of senescence (33) . In accordance with Arf 287 expression, Z/Sox9tg MEFs contained lower p53 basal expression (Fig. 3C ). In addition, 288 the expression of Ink4b and DcR2, established markers of senescence (34) , was 289 inversely correlated with Sox9 levels (Fig. Suppl 6) . 290
Next, we evaluated the consequences of altering Sox9 in response to oncogene-291 induced senescence. High levels of oncogenic H-RasV12 result in the activation of a 292 protective response that limits proliferation and enhances resistance to neoplastic 293 transformation in primary MEFs (35) . In contrast to wt MEFs, Sox9 overexpressing 294 cells were able to proliferate and generate colonies even in the presence of H-RasV12 295 (Fig. 3D ). The Ink4a/Arf locus is one of the most important defensive mechanisms 296 against oncogenic stress. In particular, H-RasV12 upregulates both Ink4a and Arf (35) . Author Manuscript Published OnlineFirst on January 13, 2012; DOI: 10.1158/0008-5472. tumors while progression to malignancy requires evading senescence. This paradigm 317 has been well characterized in the K-RasG12V conditional mouse model, where low-318 grade pre-malignant lung adenomas are strongly positive for senescence markers and 319 high-grade invasive malignant adenocarcinomas are essentially negative (34) . In this 320
context, immunohistochemical analysis of Sox9 expression revealed remarkable high 321 levels of expression exclusively in lung adenocarcinomas, while normal tissue and pre-322 malignant adenomas were for the most part SOX9 negative (Fig. 3F) (Fig. 4B,C) . This is likely to 341 reflect increased transcription and not protein stability, as we found that, compared to 342 normal control MEFs, Sox9 mRNA levels were augmented by around 10 and 15 fold in 343 immortal and transformed wt cells and between 40 and 70 times respectively in 344 Z/Sox9tg cells (Fig. 4D,E) . In contrast, SOX9 expression was significantly decreased in 345
Sox9
Δ/Δ transformed cells (Fig. 4F ). These data demonstrate that endogenous levels of 346 foci than wt cells (Fig. 4H) . In contrast, Sox9 Δ/Δ MEFs formed 3 times fewer foci in 368 response to E1a/Ras (Fig. 4I) . Since the ability of cells to grow independently of 369 adhesion is a feature of cancer cells, we analyzed whether the growth of E1a/Ras 370 transformed cells was anchorage-independent by plating cells in soft agar. Similar 371 results were obtained with Z/Sox9tg generating more colonies (Fig. 4J) . Together, our 372 findings indicate that Sox9 deregulation promotes proliferation, inhibits senescence and 373 collaborates in malignant transformation in primary MEFs. Finally, to investigate the 374 oncogenic activity of SOX9 in human colorectal cancer cells, we addressed its ability to 375 promote anchorage-independent cellular growth using the same soft agar assay. We first 376 increased SOX9 expression by transiently transfecting a plasmid carrying Sox9-IRES-377 EGFP in SW480 cells. Cells overexpressing SOX9 formed higher number of colonies 378 than cells carrying the empty vector (Fig. 4K) . In contrast, the growth of SW620 and 379 HCT116 in soft agar was inhibited by 50% with SOX9 knockdown (Fig. 4L) . In 380 (Fig. 5A, Fig. Suppl. 8 + and Z/Sox9c -mice (that is, receiving 4OHT to 398 activate the transgene or ethanol as a control, respectively) were injected with the 399 carcinogen 3-methylcholanthrene (3MC) to evaluate their susceptibility to 400 fibrosarcoma, a cancer type which reveals strong staining of Sox9 (Fig. 5C ). In this 401 context, Z/Sox9c + mice were notably more susceptible to cancer formation than their 402
Z/Sox9c
-littermates (Fig. 5D ). In particular, 6 months after 3MC treatment 100% of 403
+ mice developed fibrosarcoma compared to only 55% of Z/Sox9c -control mice. 404
Moreover, the median survival of Z/Sox9c + (4.5 months) was significantly decreased 405 compared to control mice (5.9 months) (logrank test p= 0.03) (Fig. 5D) . Finally, to 406 evaluate whether the pro-tumorigenic role of SOX9 could be extended to human cells, 407
we performed similar analysis using human colorectal cancer cell lines. We used 408 HCT116 and SW620, in which we have previously shown (see above) that knockdown 409 of SOX9 impairs cell proliferation. These results were paralleled by an attenuation of 410 tumorigenicity (Fig. 5E,F, Fig. Suppl. 8 
Sox9 directly regulates Bmi1 expression 416
With respect to the mechanisms underlying the phenotypes seen in cells with altered 417 levels of Sox9 expression, we have seen that Sox9 activity modulates the expression of 418 Ink4a and Arf tumor suppressors (see Fig. 3 ). The Polycomb-group protein Bmi1, a 419 well-established oncogene, plays an important role in proliferation, senescence and 420 carcinogenesis through its ability to repress the transcription of the Ink4a/Arf locus (37) . 421 We
Δ/Δ MEFs had lower levels (Fig. 6A ). Sox9 is known to function as a 425 transcriptional activator in several contexts, and consistent with this, the analysis of 426
Bmi1 mRNA in early-passage MEFs indicated that Sox9 modifies its levels in a manner 427 that parallels the changes in protein (Fig. 6B) . These results suggest that Sox9 exerts its 428 effect on proliferation and senescence, at least in part, through regulation of Bmi1-429 Ink4a/Arf expression. 430
With respect to transformed cells, Bmi1 paralleled Sox9 upregulation in 431 response to E1a/Ras induced transformation, with Z/Sox9tg MEFs presenting the 432 highest levels of Bmi1 (Fig. 6C,D) and Sox9 Δ/Δ MEFs the lowest (Fig. 6E,F) . Next, we 433 tested the possibility that Sox9 modulates Bmi1 expression by direct transcriptional 434 control. To test this, we performed chromatin immunoprecipitation (ChIP) assays that 435 revealed readily detectable Sox9 bound to the Bmi1 promoter in Z/Sox9tg but not in 436 wild-type control MEFs (Fig. 6G) . In addition, ChIP assays also demonstrated that Sox9 437 interacts with the Bmi1 promoter in transformed cells (Fig. 6G) 
. Our data show that 438
Bmi1 is a novel direct downstream target of Sox9 in primary and transformed MEFs and 439 may therefore represent a key mechanism mediating the role of Sox9 in tumorigenesis. 440
It has been previously reported that high levels of BMI1 are linked with 441 progression and poor prognosis in colorectal carcinoma (38, 39 contain high levels of BMI1 (Fig 7A) . Analysis of mRNA levels revealed that SOX9 446 upregulation correlated with increased BMI1 levels in colon carcinomas compared to 447 non-tumor colonic mucosa (Fig 7B) . Furthermore, the correlation analysis showed a 448 significant association between SOX9 and BMI1 expression in colorectal carcinomas 449 (Fig 7C, Fig. Suppl. 9 ). In addition, SOX9 mRNA levels correlated negatively with ARF 450 (Fig. Suppl. 9) . Next, we extended this association to human colorectal cancer cell lines. 451 BMI1 was strongly expressed in SW620, with high levels of SOX9, and it was weak in 452 SW480, with low levels of SOX9 (Fig. 7D) (Fig. 7E) . Paralleling the results observed in MEFs, 460 SOX9 regulated BMI1 expression at transcriptional level in colorectal cancer cells (Fig.  461 
7F,G). In order to test the role of BMI1 and INK4a in SOX9 regulation of cancer cells, 462
we stably inactivated BMI1 and overexpressed INK4a in SW620 cells, which possess 463 high levels of SOX9. The shRNA-mediated inhibition of BMI1 and the restoration of 464
INK4a significantly impaired proliferation and the number of colonies in soft agar (Fig.  465 7H,I), while SOX9 levels were unchanged (Fig. 7J,K) lymphoma and kidney cancers and it has been reported to behave as a tumor suppressor 479 in some melanoma cases (16) , although its expression is upregulated in others (41) (42) (43) . 480
In addition to ourselves, others have also observed SOX9 overexpression in cancers 481 from tissues such as prostate, lung, skin carcinomas and brain (12) (13) (14) (15) we have also identified SOX9 as highly expressed (Table 1 ,2). These results support the 497 idea that SOX9 copy number change might be relevant for a subgroup of samples 498 among several malignancies. At the same time, a few cases of SOX9 duplication are 499 reported in the literature that are the cause of sex reversal and brachydactyly-anonychia 500 (50, 51) , but to our knowledge these individuals have no developed cancer. However, 501 this is consistent with ectopic expression of Sox9 in mice, for which tumor incidence is 502 not increased in comparison with controls (52), but together with a transforming agent, 503 activated oncogene or event (such as chronic injury) higher levels of Sox9 significantly 504 increase the rate of developing tumors. SOX9 expression in cancer might also be due to 505 loss of repression. The changes in chromatin modifications that we found are consistent 506 with altered upstream regulation. In line with this idea, SOX9 expression in colon 507 cancer cell lines is controlled by Wnt signaling (19) , a pathway in which constitutive 508 activation generally initiates colorectal cancers (44) . 509
Mechanistically, we observed that Sox9 activity promotes proliferation and its 510 upregulation is sufficient to bypass senescence in primary MEFs. Furthermore, SOX9 511 (20, 22) . These results support the 514 idea that the mechanisms governing self-renewal and differentiation are overlapping 515 with those regulating proliferation and senescence, and are consistent with a role for 516 SOX9 in early stages of colorectal tumorigenesis. Furthermore, we found that SOX9 517 levels increase with advanced tumor stages in colorectal cancers and it cooperates with 518 activated K-Ras, an oncogene frequently found mutated during colorectal cancer 519 development (53) , to facilitate transformation and tumor progression. It is noteworthy 520 that high levels of SOX9 are associated with lower survival and adverse prognosis (17), 521 and amplification of the 17q24.3 region correlates with the transition from primary 522 colorectal cancer to metastasis (54). Collectively, these data indicate that SOX9 is 523 important in colorectal cancer progression and support its use as a potential diagnostic 524 and prognostic marker in colorectal cancers. 525
BMI1 is a key oncogene implicated in enhancing proliferation, stem cell self 526 renewal, evading senescence, and favoring multiple cancer types partly through its 527 ability to repress the transcription of INK4a and ARF (55) . Nevertheless, BMI1 plays 528 also a role in tumorigenesis through an INK4a/ARF-independent mechanism (56, 57) . 529
We found that Sox9 directly binds the Bmi1 promoter, it regulates BMI1 expression in 530
MEFs and colorectal cancer cells and its expression is associated with BMI1 levels in 531 primary colorectal carcinomas. Moreover, BMI1 inactivation partly rescues the 532 phenotypes seen in cancer cells with high levels of SOX9. These data indicates that 533 SOX9 oncogenic activity is achieved at least in part by its ability to regulate the 534 expression of BMI1 and shows that SOX9-BMI1 interactions are likely to be critical 535 events in colorectal tumor development and progression. In agreement with this, it is 536 well known that Bmi1 is a stem/progenitor cell marker involved in the transformation of 537 stem/progenitor cells in several tissues including intestinal epithelium (55, 58) . High 538 levels of BMI1 have been observed in benign adenomas and malignant carcinomas, and 539 its expression has been linked with progression, lower survival and poor prognosis in 540 colorectal cancers (38, 39, 59) . Moreover, both genes, SOX9 and BMI1, have been 541 linked to tumorigenic epithelial-to-mesenchymal transition, a mechanism causing 542 cancer metastasis, and that occurs in the most advanced colorectal cancers (40, 60) . 543
Finally, we provide evidence that some of the Sox9-Bmi1 functions are dependent on 544 
Ink4a and Arf, whose reduced expression has been associated with BMI-1 545 overexpression in human colorectal cancers (61) . In summary, our observations provide 546 direct experimental support for the oncogenic activity of SOX9, its relevance at 547 different stages of tumorigenesis, and the mechanisms involved, particularly in 548 
